- Home
- CLGN vs MRSN Comparison
CLGN vs MRSN Comparison
Compare CLGN & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- MRSN
- Stock Information
- Founded
- CLGN 2004
- MRSN 2001
- Country
- CLGN Israel
- MRSN United States
- Employees
- CLGN N/A
- MRSN N/A
- Industry
- CLGN Industrial Specialties
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- MRSN Health Care
- Exchange
- CLGN Nasdaq
- MRSN Nasdaq
- Market Cap
- CLGN 37.4M
- MRSN 36.4M
- IPO Year
- CLGN N/A
- MRSN 2017
- Fundamental
- Price
- CLGN $2.42
- MRSN $0.35
- Analyst Decision
- CLGN Strong Buy
- MRSN Buy
- Analyst Count
- CLGN 2
- MRSN 3
- Target Price
- CLGN $12.50
- MRSN $4.00
- AVG Volume (30 Days)
- CLGN 14.2K
- MRSN 3.1M
- Earning Date
- CLGN 05-28-2025
- MRSN 05-08-2025
- Dividend Yield
- CLGN N/A
- MRSN N/A
- EPS Growth
- CLGN N/A
- MRSN N/A
- EPS
- CLGN N/A
- MRSN N/A
- Revenue
- CLGN $515,000.00
- MRSN $40,497,000.00
- Revenue This Year
- CLGN $2,177.67
- MRSN N/A
- Revenue Next Year
- CLGN $56.52
- MRSN N/A
- P/E Ratio
- CLGN N/A
- MRSN N/A
- Revenue Growth
- CLGN N/A
- MRSN 9.88
- 52 Week Low
- CLGN $2.20
- MRSN $0.26
- 52 Week High
- CLGN $6.75
- MRSN $3.83
- Technical
- Relative Strength Index (RSI)
- CLGN 28.88
- MRSN 44.90
- Support Level
- CLGN $2.31
- MRSN $0.31
- Resistance Level
- CLGN $2.49
- MRSN $0.40
- Average True Range (ATR)
- CLGN 0.14
- MRSN 0.05
- MACD
- CLGN 0.02
- MRSN 0.01
- Stochastic Oscillator
- CLGN 30.94
- MRSN 68.09
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.